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Na+K+ATPaseChronic hyperglycaemia during diabetes leads to non-enzymatic glycation of proteins to form advanced
glycation end products (AGEs) that contribute to nephropathy. We describe AGE uptake in LLC-PK1 and
HK2 proximal tubule cell lines by macropinocytosis, a non-speciﬁc, endocytic mechanism. AGE–BSA induced
dorsal circular actin rufﬂes and amiloride-sensitive dextran–TRITC uptake, signiﬁcantly increased AGE–BSA–
FITC uptake (167 ± 20% vs BSA control, p b 0.01) and was ezrin-dependent. AGE–BSA–FITC uptake was
signiﬁcantly inhibited by amiloride and inhibitors of Arf6, Rac1, racGEF Tiam1, PAK1 and actin polymerisation.
AGE–BSA–FITC, Arf6 and PIP2 co-localised within dorsal circular actin rufﬂes. AGE–BSA increased PAK1 kinase
activity (212 ± 41% vs control, p b 0.05) and protein levels of Tiam1, a Rac1 activator. AGE–BSA signiﬁcantly
increased TGF-β1 protein levels (160 ± 6%, p b 0.001 vs BSA), which were signiﬁcantly inhibited by inhibitors
of Arf6 (82 ± 19%, p b 0.001 vs AGE) and actin polymerisation (107 ± 11%, p b 0.001 vs AGE), suggesting
AGEs partially exert their proﬁbrotic effects via macropinocytosis. PAK1 and PIP5Kγ siRNA signiﬁcantly
decreased AGE–BSA–FITC uptake (81 ± 6% and 64 ± 7%, respectively, p b 0.05 vs control for both), and
AGE-stimulated TGF-β1 protein release (99 ± 15% and 49 ± 8%of control, p b 0.05 and p b 0.001, respectively).
Inhibition of AGE uptake by macropinocytosis inhibitors and a neutralising TGF-β antibody, reversed the
AGE-induced decrease in surface Na+K+ATPase, suggesting AGE uptake by macropinocytosis may contribute
to diabetic kidney ﬁbrosis and/or EMT by modulating this pump. Understanding methods of cellular uptake
and signalling by AGEs may lead to novel therapies for diabetic nephropathy.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The development of chronic diabetic complications, including
nephropathy, correlates with nonenzymatic glycation of proteins, lipids
and nucleic acids, which results in the accumulation of advanced
glycation end products (AGEs) [1–3]. In animal models, injection of
AGEs leads to renal changes similar to those of diabetic nephropathy,
while interfering with AGE formation reduces diabetic complications
[4–6]. AGE formation and accumulation precede diabetic renal disease
suggestingAGEs have a role in the pathogenesis of diabetic nephropathy
[2]. Additionally, serum and tissue AGE levels are increased in diabetic
nephropathy, and AGEs cause renal cell dysfunction in vitro [7–10].s; BSA, bovine serum albumin;
; HK2, human kidney proximal
rowth medium; PIP5Kγ, phos-
ivated kinase; Arf6, adenosine
y and Diabetes, Alfred Hospital,
6 2387; fax: +61 3 9076 3782.
l rights reserved.The mechanisms of tissue damage caused by AGEs are incompletely
understood, although they include both receptor-independent modiﬁ-
cation of long-lived proteins as well as cell-speciﬁc, receptor-mediated
pathways.
Although endocytosis of glycated albumin by rat endothelial cells
has been described [11], cellular uptake of AGEs has been little
studied. Glycated albumin was preferentially bound, internalised and
transported in capillaries of isolated, perfused rat lungs [12], and
labelled AGE–BSA was internalised in cultured bovine endothelial cells
[13]. In infused mouse cerebral cortex, glycated albumin localised to
endosomes of brain microvascular endothelial cells [14].
Plasma proteins such as albumin are normally ﬁltered by the
glomerulus and reabsorbed by proximal tubule cells. In diabetic
nephropathy, serum and tissue AGE levels are elevated [7,15] and
plasma levels rise with declining glomerular ﬁltration rate [16]. One
study showed that AGE-peptides are ﬁltered and reabsorbed by proxi-
mal but not distal tubule epithelial cells [17], but there are few studies
of AGE uptake by proximal tubule cells. Increased intracellular accumu-
lation and decreased degradation of AGE modiﬁed proteins as well as
abnormal lysosomal function were noted in cultured proximal tubule
cells, suggesting abnormal protein processing by these cells may con-
tribute to diabetic renal hypertrophy and nephropathy [18].
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of large volumes of extracellular ﬂuid to form macropinosomes at the
base of cell membrane rufﬂes [19]. Macropinocytosis is induced by
growth factor receptor-mediated signalling events in ‘non-professional’
phagocytes such as epithelial cells, but occurs constitutively in ‘profes-
sional’ phagocytic macrophages and dendritic cells [20]. It is essential
for bacterial and viral uptake into cells and antigen presentation in
dendritic cells. Macropinosomes are readily labelled by a large, ﬂuid-
phase marker, dextran–FITC. As they mature, macropinosomes acquire
markers of early and late endosomes before fusing to classical
lysosomes.
ADP-ribosylation factor 6 (Arf6) colocaliseswith phosphatidylinositol
4-phosphate 5-kinase (PIP5K) at the plasma membrane in actin-rich
protrusions and rufﬂes [21,22]. Arf6-controlled PIP5K activity and phos-
phatidylinositol 4,5 phosphate (PIP2) turnover are critical for mem-
brane trafﬁcking between the plasma membrane and endosomes [23].
During macropinocytosis, PIP2 turnover recruits and regulates many
Arf and Rac guanine exchange factors (GEFs) to control actin dynamics
[24,25]. p21-activated kinase (PAK1), downstreamof Rac1, a RhoGTPase,
is necessary for macropinocytosis [26]. Here we report, for the ﬁrst time,
the uptake of AGEs by proximal tubule cells via macropinocytosis and
show that this involves Arf6, Rac1 and its GEF Tiam1, PIP5Kγ/PIP2, and
PAK1. We also show the upregulation of transforming growth factor
beta (TGF-β1) and downregulation of surface expression of Na+K+
ATPase by AGEs is, at least in part, mediated via macropinocytosis,
suggesting that this uptake mechanism may contribute to ﬁbrosis and
is thus a potential new therapeutic target in diabetic kidney disease.
2. Materials and methods
2.1. Materials
Tissue culture plastics and reagents were purchased from Nunc
(Roskilde, Denmark) and Trace Biosciences (Melbourne, Australia),
respectively. All other laboratory reagents were purchased from Sigma
Corporation (St Louis, MO) unless otherwise speciﬁed.
2.2. AGE preparation
AGE–BSA was prepared as described previously with modiﬁcations
[27]. Brieﬂy, BSA (10 mg/ml) or RNAse (10 mg/ml) was incubated
with D-glucose (90 g/l) in 0.4 M phosphate buffer at 37 °C for 12 or
6 weeks, respectively. Preparations were lyophilised, resuspended in
water and dialysed against phosphate buffered saline (PBS) to remove
free glucose. Control BSA or RNAsewasprepared by identical incubation
without glucose. Glycation was assessed by characteristic ﬂuorescence
(excitation 370 nm, emission 440 nm) with a 7–28-fold increase
in ﬂuorescence of AGE–BSA compared to BSA. Methylglyoxal–BSA
(MGO–BSA) was prepared as described [28]. Brieﬂy, 0.22 g BSA was
incubated with or without 0.54 ml of 40 (w/v)% methylglyoxal in
30 ml 0.4 M phosphate buffer for 24 h and then dialysed against
30 mM ammonium bicarbonate pH 7.8 to remove free methylglyoxal.
2.3. Cell culture
Porcine LLC-PK1 and human HK2 kidney proximal tubule epithelial
cell lines were obtained from the American Tissue Culture Collection
(ATCC, Rockville, MD) [29,30]. Transfection of LLC-PK1 cells with
dominant-negative N-ezrin or vector control has been described previ-
ously [9]. Cells were cultured in 5% CO2 in growth medium (GM)
consisting of Dulbecco's modiﬁed Eagle's medium (DMEM) containing
4.5 g/l glucose, 2 mM L-glutamine, 5000 IU/l penicillin, 5 mg/l strepto-
mycin, 125 U/l Fungizone, 2.2 g/l sodium bicarbonate supplemented
with 10% foetal calf serum (FCS). For experiments under serum-free
conditions, cells were cultured in serum-free medium (SFM) consisting
of DMEM with antibiotics, glutamine and 0.5 g/l BSA.2.4. Inhibitors
Inhibitors and their maximal concentrations were: GGTI-287
(4.8 μM, Calbiochem, CA) [31] and NSC23766 (19 μM, Calbiochem)
[32] for Rac1, Arf6(2–13) inhibitory peptide (2 μM, Calbiochem) [33],
IPA-3 (20 μM, Calbiochem) [34] for PAK1, Cytochalasin D (3.9 μM,
Calbiochem) [34] for actin polymerisation and amiloride (0.16 mg/ml,
Calbiochem) [35] for the Na+/H+ exchanger. Since some inhibitors
were dissolved in DMSO or ethanol, we tested the effects of these sol-
vents in all assays and found that they had no effect.
2.5. Immunoﬂuorescence
LLC-PK1 cells were grown on glass coverslips. After incubation in
SFM overnight, cells were treated with 40 μM BSA or AGE–BSA for
30 min. After ﬁxation in 3.7% paraformaldehyde/PBS for 10 min, cells
were incubated in 0.1% Triton X-100/PBS for 5 min, blocked with 1%
BSA/PBS for 15 min and incubated with a 1/50 dilution of anti-PIP2 or
anti-Arf6 antiserum (Echelon Biosciences, Salt Lake City, UT and Santa
Cruz, CA, respectively), or a 1/20 dilution of anti-Na+K+ATPase α
subunit (Sigma, clone M7-PB-E9) in 1% BSA/PBS overnight at 4 °C.
Staining with ﬂuoroscein isothiocyanate (FITC)- or tetramethyl rhoda-
mine isothiocyanate (TRITC)-labelled secondary antibody (Invitrogen),
respectively, was performed for 1 h at a 1/1000 dilution. Polymerised
actin was visualised using phalloidin-TRITC (1/200 dilution in PBS for
20 min) or phalloidin-Alexa 488 (Molecular Probes; 1/20 dilution in
PBS for 1 h). For dextran–TRITC uptake studies, cells incubated in SFM
for 24 h were pre-incubated with amiloride (0.8 mg/ml) for 15 min
and then treated with 40 μM BSA or AGE–BSA together with 1 mg/ml
dextran–TRITC (MW 70,000) for 30 min. For Na+K+ATPase studies,
cells incubated in SFM for 24 h were pre-incubated with amiloride
(0.8 mg/ml), cytochalasin D (3.9 μM) or GGTI-287 (4.8 μM) for 30 min,
or with 30 μg/ml of a TGF-β pan speciﬁc antibody (R&D Systems, MN,
USA) or control normal rabbit serum for 1 h. After washing in PBS and
staining with DAPI (1/15,000 dilution in PBS) for 1 min, slides were
rinsed in water, mounted in Permaﬂuor (Beckman-Coulter, Marseille,
France) and viewed by ﬂuorescence microscopy using an Olympus
BX51 ﬂuorescence microscope with Olympus DP70 digital camera. At
least 3 ﬁelds per treatment were imaged and images merged using Fiji
Image J.
2.6. AGE–BSA–FITC uptake
AGE–BSA was labelled with FITC [36]. Brieﬂy, 5 mg FITC was
solubilised in 40 μl 1 M NaOH before adding 0.46 ml PBS and 25 mg
AGE–BSA. The mixture was incubated at 4 °C for 24 h and dialysed
extensively against PBS. AGE–BSA–FITC was aliquoted and stored at
−20 °C until use. Covalent binding of FITC to protein was conﬁrmed
by SDS-10%-PAGE followed by visualisation under UV light (not shown).
For AGE–BSA–FITC uptake studies, cells grown in 24-well plates
were preincubated in SFM for 24 h. LLC-PK1 cells were pre-treated
with inhibitors for 15 min before addition of 40 μM BSA or AGE–BSA,
together with 100 μg/ml of AGE–BSA–FITC for a further 45 min or as
indicated. Cells were washed twice in Hank's Buffered Salt Solution
(HBSS) followed by PBS. Lysates were collected in 1% Triton X-100 per
well and spun at 10,000 ×g for 15 s. Fluorescence in cell lysates was
measured by spectroﬂuorometry and normalised for total cell protein.
2.7. PAK1 activation
LLC-PK1 cells were treated with 40 μM BSA or AGE–BSA for 24 h.
Cells were lysed in lysis buffer (10 mM Tris–HCl pH 8, 50 mM NaCl,
30 mM NaF, 1 mM EDTA, 1% Triton X-100 containing 0.2 mM
Na3VO4, 1 μg/ml leupeptin, 0.7 μg/ml pepstatin A, 1 mM PMSF, 1 μg/ml
aprotinin and 20 mM β-glycerophosphate) and centrifuged for 30 s at
10,000 ×g. Protein assays were performed on supernatants. 40 μl of
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4 °C. Protein A sepharose beads (50 μl of 50% slurry) were then added
for a further 1 h at 4 °C. After centrifugation at 10,000 ×g for 30 s,
beads were washed 3 times in lysis buffer and once in kinase buffer
(50 mM Hepes pH 7.3, 10 mM MgCl2 and 2 mM MnCl2). Beads were
mixed with 30 μl kinase buffer containing 20 μMATP, 10 mg/ml myelin
basic protein (MBP, Sigma) and 1 μl of dATP [α-32P] (Perkin Elmer, MA),
and then incubated at room temperature and 37 °C for 10 min each.
Proteins were separated by SDS-14%-PAGE and MBP phosphorylation
visualised by exposure to X-ray ﬁlm.
2.8. Western blotting
Cells were treated with PBS vehicle, 40 μM BSA or AGE–BSA for
30 min and cell lysates prepared in lysis buffer containing 50 mM
HEPES, 0.05 M NaCl, 0.05% Tween 20, 1% Triton X-100 and complete
protease inhibitor cocktail (Roche, IN), centrifuged at 12,500 rpm
for 1 min and supernatants stored at−20 °C in non-reducing sample
buffer until use. Proteins (100 μg/sample) were separated by SDS-8%-
or 10%-PAGE andWestern blottedwith rabbit anti-Tiam1 (Calbiochem)
or rabbit anti-PAK1 (N-20, Santa Cruz) diluted 1/1000, and anti-β-actin
(Sigma) diluted 1/5000, in 1% BSA/TBST (50 mMTris, 0.15 MNaCl, 0.1%
Tween 20, pH 7.4) and then secondary-HRP linked antibody, followed
by detection using enhanced chemiluminescence (Supersignal West
Pico; Pierce, Rockford, IL) and exposure to X-ray ﬁlm.
2.9. TGF-β1 ELISA
Subconﬂuent HK2 cells were pre-treated with 2 μM Arf6(2–13)
inhibitory peptide, 3.9 μM cytochalasin D, 4.8 μM GGTI-287 or 20 μM
IPA-3 in SFM for 1 h before treatment with 40 μM BSA or AGE–BSA in
fresh SFM for 24 h. Conditioned media (CM) were collected and spun
for 30 s at 10,000 ×g. Total TGF-β1 was measured using a TGF-β1 Emax
ELISA (Promega, WI) after preactivation by acidiﬁcation with 1 M HCl
(1 μl per 100 μl CM) for 15 min, followed by neutralisation with 1 M
NaOH.
2.10. siRNA
The PIP5Kγ siRNA (Dharmacon, Thermo Scientiﬁc, CO) sequence
was designed from conserved human/mouse sequences [37] but
did not decrease PIP5Kγ levels in porcine LLC-PK1 cells (results not
shown). We therefore used human HK2 cells for PIP5Kγ siRNA experi-
ments and achieved 90% transient knockdown [10]. Human PAK1 siRNA
(Dharmacon) resulted in 65% transient knockdown inHK2 cells. Control
non-targeting, PAK1 or PIP5Kγ siRNA (200 nM) were pre-incubated
with Dharmafectene 1 (8 μl/ml, Dharmacon) in 0.2 ml SFM for
30 min, before addition to subconﬂuent HK2 cells in 0.6 ml GM in one
well of a 6-well plate. After 48 h, cells were seeded into 24-well plates
and used in AGE–BSA–FITC uptake or TGF-β1 assays as described above.
2.11. Statistics
Data were analysed by unpaired t-test or ANOVA. Post-hoc analyses
were performed using Fisher's protected least signiﬁcant difference test.
Where necessary, datawere log transformed prior to ANOVA to stabilise
variance. A p value of b0.05 was considered signiﬁcant. Results are
expressed as mean ± SEM. Experiments were performed at least 3
times unless otherwise indicated.
3. Results
3.1. AGEs induce circular rufﬂes in proximal tubule cells
Glycated bovine serum albumin (AGE–BSA) induced the formation
of circular rufﬂes representing rings of polymerised actin on the surfaceof LLC-PK1 cells (Fig. 1A,B). Incubation with FITC conjugated AGE–BSA
(AGE–BSA–FITC) resulted in its co-localisationwith circular actin rufﬂes
(Fig. 1C). A time course showed that the number of rufﬂes increased
with time and that AGE–BSA induced a signiﬁcantly greater number
of rufﬂes than BSA after 30 min (Fig. 2A, B). Over a 60 min time course,
AGE–BSA–FITC uptake also signiﬁcantly increased with time and AGE–
BSA induced a signiﬁcantly greater increase than BSA overall (p =
0.013, Fig. 2C). Of the individual time points, AGE was only signiﬁcantly
greater than BSA at 60 min (p b 0.05).
3.2. AGEs induce dextran–TRITC and AGE–BSA–FITC uptake
via macropinocytosis
Uptake of high molecular mass dextran–TRITC is a deﬁning
characteristic of macropinocytosis [38]. Since signiﬁcant rufﬂe forma-
tion and increasing uptake of AGE–BSA–FITC were noted at 30 min,
we studied dextran–TRITC uptake in LLC-PK1 cells at this time point.
AGE–BSA increased uptake of dextran–TRITC compared to BSA after
30 min and this was reduced by amiloride (Fig. 3A), an inhibitor of
macropinocytosis [35]. AGE–BSA did not induce increased uptake of
dextran–TRITC after 5 min (results not shown). AGE–BSA also signiﬁ-
cantly induced AGE–BSA–FITC uptake by LLC-PK1 cells after 45 min
(167 ± 20% of BSA control, p b 0.01) and this was also inhibited by
amiloride (106 ± 20%, p b 0.05 vsAGE–BSA, Fig. 3B). Together, these re-
sults suggest that AGE–BSA induces its own uptake viamacropinocytosis
[38].
3.3. Other AGEs stimulate AGE–BSA–FITC uptake, which is ezrin-dependent
Other AGEs, methylglyoxal–BSA (MGO–BSA) and AGE-ribonuclease
(AGE-RNAse), also signiﬁcantly stimulated uptake of AGE–BSA–FITC
compared to their BSA or RNAse controls, respectively (175 ± 21%
and 126 ± 6% respectively, p b 0.05 for both, Fig. 4A). This indicates
that the AGE moiety of each protein is responsible for the uptake of
AGE–BSA in proximal tubule epithelial cells.
Ezrin, which links membrane proteins to the actin cytoskeleton, is
required for macropinocytosis by epidermal growth factor-stimulated
epidermoid cancer cells [39]. AGE–BSA–FITC uptake was signiﬁcantly
reduced in two dominant negative N-ezrin-transfected LLC-PK1 cell
lines compared to vector-control cells (73 ± 8% and 68 ± 10% of
vector control, p b 0.05 for both, Fig. 4B). Thus, macropinocytosis of
AGE–BSA in LLC-PK1 cells is at least partially ezrin-dependent.
3.4. AGE–BSA–FITC uptake is regulated by actin polymerisation, Arf6 and
Rac1
Arf6(2–13) peptide, an Arf6 inhibitor, signiﬁcantly decreased AGE–
BSA–FITC uptake in LLC-PK1 cells (80 ± 11% vs 135 ± 10%, p b 0.001,
Fig. 5A). Cytochalasin D, an inhibitor of actin polymerisation, had a
similar effect (98 ± 8% vs 139 ± 12% of BSA control, p b 0.01, Fig. 5A).
Thus uptake of AGE–BSA by macropinocytosis is regulated by Arf6 and
actin polymerisation.
Amiloride, which decreased AGE–BSA–FITC uptake (Fig. 3A,B), also
inhibits Rac1 signalling [35]. GGTI-287, which inhibits Rac1 activity,
signiﬁcantly inhibited AGE-induced uptake of AGE–BSA–FITC by LLC-
PK1 cells (107 ± 22% vs 155 ± 9%, p b 0.05, Fig. 5B). Rac1 is activated
by various Rac speciﬁc guanine nucleotide exchange factors (GEFs),
including Tiam1. AGE–BSA increased Tiam1 expression after 24 h
(Fig. 6A). NSC23677, which inhibits the interaction of Tiam1 with Rac1,
also decreased AGE–BSA–FITC uptake (129 ± 16% vs 168 ± 14%,
p b 0.05, Fig. 5B). AGE–BSA also signiﬁcantly induced activation of the
Rac1 effector, PAK1, as detected by increased phosphorylation of myelin
basic protein (MBP) (212 ± 41% p b 0.05 vs BSA, Fig. 6B). Furthermore,
AGE-induced uptake of AGE–BSA–FITC was signiﬁcantly inhibited by a
PAK1 inhibitor, IPA-3 (75 ± 6% vs 121 ± 7%, p b 0.001, Fig. 5B). These
AGE-BSA-FITCC ACTIN, AGE-BSA
A BSA B AGE-BSA
Fig. 1. AGE–BSA induces circular rufﬂe formation. (A, B) LLC-PK1 cells were incubated with A 40 μM BSA or B AGE-BSA for 60 min. Cells were stained for polymerised actin using
phalloidin-Alexa 488, and nuclei were stained with DAPI. Dorsal circular rufﬂes were noted (arrows) by ﬂuorescence microscopy. (C) LLC-PK1 cells were pre-treated with 40 μM
AGE-BSA for 48 h followed by the addition of 100 μg/ml AGE–BSA–FITC for 2 min. Cells were stained for polymerised actin with phalloidin-TRITC and dorsal circular rufﬂes noted
(arrows) to which AGE–BSA–FITC localised. Bar 50 μm.
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uptake by macropinocytosis.
3.5. Localisation of PIP2 and Arf6 to dorsal circular rufﬂes
Both PIP2 and Arf6 are found in concentric patterns within mem-
brane protrusions engulﬁng bacteria during their phagocytosis [40].
Similarly, staining of both PIP2 and Arf6 was noted in a circular pattern
within actin-stained macropinosomes (Fig. 7A,B).
3.6. Effect of AGE uptake on TGF-β1 levels
TGF-β1 upregulation leading to epithelial-to-mesenchymal transi-
tion (EMT) of proximal tubule cells and ﬁbrosis is a feature of diabetic
kidney disease [41]. AGEs have been shown to stimulate TGF-β1 produc-
tion in vivo and in vitro via signalling through the receptor for AGEs,
RAGE [27,42]. AGE–BSA increased TGF-β1 levels in media conditioned
by HK2 cells (160 ± 6% AGE vs BSA, p b 0.001; Fig. 8). We tested
macropinocytosis inhibitors for their effects on AGE-induced TGF-β1
accumulation. Cytochalasin D and Arf6(2–13) peptide both abrogated
the AGE–BSA-induced increase in TGF-β1 protein levels in HK2 cells
(82 ± 19% and 107 ± 11% respectively, both p b 0.001 vs AGE; Fig. 8).
Inhibitors of macropinocytosis thus decreased TGF-β1 accumulation in
HK2 cells.
3.7. PAK1 and PIP5Kγ siRNA inhibit AGE–FITC uptake and AGE-induced
TGF-β1 accumulation
We recently found that AGEs upregulated PIP5Kγ activity in proxi-
mal tubule cells [10]. PIP5K activity is regulated by Arf6 and mediates
formation of PIP2, which is required for membrane trafﬁcking at the
plasma membrane [43]. Since Arf6 and PAK1 inhibitors decreased AGE–BSA–FITC uptake and PIP2 stained strongly within macropinosomes, we
sought to determine the effects of PIP5K and PAK1 knockdown on
AGE–BSA–FITC uptake.
Transient transfection with PIP5Kγ siRNA achieved a ~90% reduction
in protein level as previously shown [10], whereas transient transfection
with PAK1 siRNA achieved a ~65% reduction (Fig. 9A). Basal AGE–BSA–
FITCuptakewas signiﬁcantly inhibited inHK2 cells transiently transfected
with either PAK1 or PIP5Kγ siRNA (81 ± 6% and 64 ± 7%, respectively,
p b 0.05 vs control for both, Fig. 9B). Transient PAK1 and PIP5Kγ knock-
down also inhibited AGE-stimulated TGF-β1 accumulation (99 ± 15%,
p b 0.05, and 59 ± 9%, p b 0.001, Fig. 9C).
3.8. Uptake of AGE–BSA by macropinocytosis downregulates surface
expression of the α1 subunit of Na+K+ATPase
We recently showed that AGEs downregulated surface expression of
Na+K+ATPase [10]. To assess the role of AGE uptake bymacropinocytosis
in this process, we studied it after a 30 min incubation with AGE–BSA, as
this time corresponded to the signiﬁcant formation of rufﬂes as shown
above, as well as marked downregulation of the α1 subunit of
Na+K+ATPase by AGE–BSA [10]. We conﬁrmed that AGE–BSA dramati-
cally decreased surface expression of the α1 subunit of Na+K+ATPase
using immunoﬂuorescencemicroscopy (Fig. 10A). Further, diverse inhib-
itors of AGE–BSAmacropinocytosis as established in this paper prevented
this effect of AGE–BSA (Fig. 10A). Furthermore, a neutralising antibody to
TGF-β reversed the AGE–BSA effect, suggesting that TGF-β is involved
(Fig. 10B).
4. Discussion
Macropinocytosis is a form of endocytosis that results in the
non-selective uptake of extracellular macromolecules, infectious
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Fig. 2. AGE–BSA induces circular rufﬂe formation and AGE–BSA–FITC uptake over time. A and B LLC-PK1 cells were incubated with 40 μM BSA or AGE–BSA from 5 to 60 min. Cells
were labeled for polymerised actin using phalloidin-Alexa 488 and nuclei stained with DAPI. Bar 50 μm *p b 0.05 vs BSA, **p b 0.01 vs BSA C LLC-PK1 cells were incubated with
40 μM BSA (white) or AGE–BSA (black) for 5 to 60 min in the presence of 100 μg/ml AGE–BSA–FITC. Cell lysates were collected and assayed by spectroﬂuorometry. Experiments
were performed 5–6 times in triplicate and results normalised to protein content and expressed as a percentage of the 5 min BSA control. *p b 0.05 vs BSA.
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stimulation, Rac1 induces branching of actin ﬁlaments, resulting
in membrane rufﬂing at the dorsal surface. Extended membrane
rufﬂes fold with the plasma membrane, which generates large endo-
cytotic vesicles termed macropinosomes. Here we report that in renal
proximal tubule cells, AGEs are taken up at least partially via increased
macropinocytosis. This may be relevant since advanced glycation is im-
plicated in the development of diabetic nephropathy. Serum and tissue
AGE levels are elevated in diabetic nephropathy [7,15] while plasma
levels of the AGEs, CML and CEL, rise with decreasing glomerular ﬁltra-
tion rate [16].
Normal proximal tubular function leads to the reabsorption of
plasma proteins that are ﬁltered by the glomerulus. Sources of extra-
cellular glycated proteins to which proximal tubules may be exposed
include circulating proteins and lipoproteins, which are reversibly
modiﬁed to form early glycation products and then irreversibly modi-
ﬁed to form AGEs [15,44,45]. However, there are few studies of AGE
uptake by proximal tubule cells. One study showed that AGE-peptides
are ﬁltered and reabsorbed by proximal but not distal tubule epithelial
cells [17]. Proximal tubule cells, but not other cell types including distal
tubule cells, showed increased apical uptake of the AGE pentosidine,which was also detected in the cytoplasm [46]. Intravenously adminis-
tered pentosidine was ﬁltered by glomeruli and then reabsorbed by
proximal tubules where it was degraded, modiﬁed and eventually
excreted into the urine [47]. Immunohistochemical studies demonstrated
that pentosidine was found in proximal renal tubules from normal
subjects and those with diabetes [46,48]. Proximal tubule cells thus
take up AGEs in vitro and in vivo. Glycated proteins were also taken up
by other cells and tissues, such as rat endothelial cells, rat lung capil-
laries, cultured bovine endotheliumandbrainmicrovascular endothelial
cells [11–14], while diabetic retinal capillaries were shown to have
increased micropinocytic activity [49,50].
We found that glycated BSA (AGE–BSA) induced the formation of
circular dorsal rufﬂes in proximal tubule cells, to which AGE–BSA–FITC
co-localised. The formation of circular dorsal rufﬂes indicates the occur-
rence of macropinocytosis [38], which was conﬁrmed by induction of
amiloride-sensitive uptake of dextran–TRITC by AGE–BSA, a classic
marker of macropinocytosis [35,38]. AGE–BSA also induced its own
cellular uptake by ~70% in an amiloride-sensitive manner.
Overexpression of a dominant negative N-ezrin reduced AGE–
BSA–FITC uptake. Since ezrin is required for macropinocytosis
in LLC-PK1 cells, this suggests AGE–BSA uptake may occur by
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was reduced by only ~30%. This may relate to the fact that ezrin
was incompletely down-regulated, by 66% and 88%, in our stable
transfectants [9]. This is broadly consistent with the observation
by D'Angelo et al., 2007, that macropinocytosis was reduced by
58% after complete ezrin knockdown [39].
In contrast to our ﬁndings, macropinocytosis was reportedly
decreased in macrophages grown under high glucose conditions [50].
However, TRITC–albumin was used in that study [50], so that receptor-
mediated endocytosis may also have contributed to uptake, thereby
explaining the apparent discrepancy with our ﬁndings. Alternatively,
there may be cell-speciﬁc determinants of macropinocytosis.
A number of glycated proteins and different AGEs increased uptake
of AGE–BSA in the present study. This indicates that it is the AGEmoiety
of each protein that is responsible for AGE–BSA uptake in proximal
tubule epithelial cells. This concurs with the observation that a range
of distinct AGEs, including AGE-peptides [17], pentosidine [46,48] and
glycated albumin [11–14], are taken up by proximal tubule and other
cell types in vitro and in vivo.
Our inhibitor studies suggest a macropinocytosis pathway involved
in AGE–BSA uptake as discussed in the following paragraphs. For conve-
nience, we have organised the discussion according to the following
schema, although it is not deﬁnitive: AGE→ Arf6→ PIP5Kγ→
Tiam1→ Rac1→ PAK1→ actin reorganisation→ AGE uptake by
macropinocytosis→ TGFβ1 release→ ↓ surface Na+K+ATPase.
ADP ribosylation factor 6 (Arf6) belongs to the Arf family of Ras-
related GTP-binding proteins. It is involved in membrane trafﬁcking
during receptor-mediated endocytosis, endosomal recycling, exocytosis
of secretory granules and has a role in actin-richmembrane protrusionsand rufﬂes [21,51,52]. Of relevance to diabetes, Arf6 has been implicated
in protein kinase C β1 activation in mesangial cells grown under high
glucose conditions [53]. We found concentric localisation of Arf6 within
actin rufﬂes surrounding internalised AGE–BSA–FITC that resembled
the localisation of these molecules relative to internalised Chlamydia
[40]. The localisation of Arf6 within rufﬂes and inhibition of AGE–BSA
uptake by an Arf6 inhibitory peptide suggest a role for Arf6 in AGE
macropinocytosis [23].
Arf6 induces changes in membrane phospholipids to allow Rac
activation and actin remodelling. Arf6 colocalises with PIP5K at the
plasma membrane in protrusions and rufﬂes [22]. Arf6 can directly
activate PIP5Kα and so increase localised levels of PIP2 that binds to
the PH domains of racGEFs such as Tiam1 [22]. Arf6-controlled PIP5K
activity and PIP2 turnover are critical formembrane trafﬁcking between
the plasmamembrane and endosomes [23].Wepreviously showed that
AGEs activated PIP5Kγ in proximal tubule cells [10], while PIP5Kγ
knockdown inhibited AGE–BSA uptake, which support a role for PIP5Kγ
in AGE macropinocytosis.
We also found PIP2 within actin rufﬂes, consistent with the require-
ment of PIP2 turnover for macropinocytosis [24] and phagocytosis [25].
PIP2 recruits and regulates many ArfGEFs and RacGEFs to control actin
dynamics. Membrane association of Tiam1, a RacGEF, is mediated by
PIP2 binding to its N-terminal pleckstrin homology domain [54], and
PIP2 is a potent stimulator of Tiam1 activity [55]. PIP2 also targets pro-
teins with polybasic clusters such as Arf6 and Rac1 to the plasmamem-
brane [56]. Membrane association is required for GDP/GTP exchange on
Rac1 [54]. Since Tiam1mediates Rac1 activation andmembrane rufﬂing
[57], PIP2 may localise Tiam1 in the macropinosome, which in turn
localises Rac1 activity. We found that levels of Tiam1 protein increased
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Fig. 4. Different AGEs induce AGE–BSA–FITC uptake in an ezrin-dependent manner. A
LLC-PK1 cells were incubated with 40 μM BSA (white), MGO–BSA (black), RNAse (light
grey) or AGE–RNAse (dark grey) for 45 min in the presence of 100 μg/ml AGE–BSA–
FITC. Cell lysates were collected and measurements performed by spectroﬂuorometry.
Experiments were performed 4 times in triplicate and results normalised to protein
content and expressed as a percentage of the respective BSA or RNAse control. *p b 0.05
vs BSA control, #p b 0.05 vs RNAse control. B Two independent LLC-PK1 cell lines (1 and
2) were stably transfected with vector only (black) or with vector expressing dominant
negative N-ezrin (grey). Cells were incubated with 100 μg/ml AGE–BSA–FITC for 45 min.
Cell lysates were collected and assayed by spectroﬂuorometry. Experiments were
performed 6–7 times in triplicate and results normalised to protein content and expressed
as a percentage of vector control. *p b 0.05 vs vector control 1, #p b 0.05 vs vector control 2.
A
0
50
100
150
200
A
G
E-
BS
A-
FI
TC
 u
pt
ak
e
 
(%
 B
SA
)
AGE AGEAGE+CYTO. D AGE+ARF6(2-13)
##
**
###
*
AGE
+IPA-3
AGE
+GGTI.
AGE
+NSC.
B
A
G
E-
BS
A-
FI
TC
 u
pt
ak
e 
(%
 B
SA
)
AGE AGE AGE
0
50
100
150
200
*
###
#
#
*
**
Fig. 5. Uptake of AGE–BSA in LLC-PK1 cells is regulated by inhibitors of actin polymer-
isation, Arf6, Rac1 and PAK1. A LLC-PK1 cells were pre-treated with 0.2% DMSO vehicle
control (black), 3.9 μM cytochalasin D (grey) or 2 μM Arf6(2–13) inhibitory peptide
(grey) for 15 min before incubation with 40 μMAGE–BSA ± inhibitors in the presence
of 100 μg/ml of AGE–BSA–FITC for 45 min. Cell lysates were collected and uptake
measured by spectroﬂuorometry. Experiments were performed 4 times in triplicate
and results expressed as a percentage of 40 μM BSA control (not shown). *p b 0.05,
**p b 0.01 vs BSA control, ##p b 0.01, ###p b 0.001 vs AGE–BSA. B LLC-PK1 cells
were pretreated with 0.4% DMSO vehicle control (black), 4.8 μM GGTI-287 (grey),
19 μM NSC23766 (grey) or 20 μM IPA-3 (grey) for 15 min before incubation with
40 μM AGE–BSA ± inhibitors in the presence 100 μg/ml of AGE–BSA–FITC for 45 min.
Cell lysates were collected and assayed by spectroﬂuorometry. Experiments were
performed 4–7 times in triplicate and results normalised to protein content and expressed
as a percentage of 40 μM BSA control (not shown). *p b 0.05, **p b 0.01, vs BSA control,
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inducing Tiam1 transcription, although earlier time points were not
studied. Inhibition of Tiam1 by NSC23766 inhibited AGE–BSA uptake,
suggesting that Tiam1 contributed to glycated protein uptake by
macropinocytosis.
Growth factor-inducedmembrane rufﬂing is regulated by Rac1 [58].
Rac1 induces macropinocytosis in ﬁbroblasts [59], and bacterial phago-
cytosis depends on Rac1 activation [60–62]. We found that GGTI-287,
an inhibitor of Rac1 activity, decreased AGE–BSA–FITC uptake in
LLC-PK1 cells, suggesting that Rac1 regulates macropinocytosis of
AGE–BSA. Intriguingly, amiloride, which decreased dextran–TRITC and
AGE–BSA–TRITC uptake, was recently shown to inhibit Rac1 signalling
[35]. Arf6 is involved in translocation of Rac1 to the plasmamembrane,
allowing rufﬂe formation [63–65]. These ﬁndings suggest that Tiam1
activates Rac1 to upregulate macropinocytosis of AGE–BSA.
PAK1 is a downstream effector of Rac1 and is essential for
macropinocytosis [26]. AGE–BSA stimulated PAK1 activity while AGE–
BSA–FITC uptake was decreased by IPA-3, an inhibitor of PAK1, and
by PAK1 knockdown. These results provide further evidence that
macropinocytosis underlies AGE–BSA uptake by proximal tubule cells.
TGF-β is responsible for renal epithelial to mesenchymal transi-
tion (EMT) and ﬁbrosis, which are features of diabetic nephropathy
[66]. Inhibition of actin polymerisation, Arf6, PAK1 and PIP5Kγ
also inhibited AGE-induced TGF-β1 accumulation, suggesting uptake
of AGEs viamacropinocytosis by proximal tubule cells may contributeto a proﬁbrotic environment. Indeed, uptake of apoptotic cells by
macropinocytosis has also been linked to TGF-β1 secretion [67].
Na+K+ATPase is a basolateral membrane pump that maintains Na+
and K+ gradients across the plasma membrane to ensure proximal tu-
bule cell homeostasis. In diabetes, Na+K+ATPase levels are reduced in
erythrocytes of patients and also in cell and animal models [68,69].
We have recently shown that Na+K+ATPase is downregulated by
AGEs, by internalisation via clathrin-mediated endocytosis within mi-
nutes of exposure [10]. Post-translational loss of the β1 subunit of
Na+K+ATPase in LLC-PK1 cells has been linked to the development of
TGF-β1-mediated EMT [70]. It was also observed that both α1 and β1
subunits of Na+K+ATPase were decreased in renal biopsies from
diabetic nephropathy patients [70]. We found that macropinocytosis
inhibitors reversed the AGE-induced decrease in surface Na+K+ATPase,
suggesting that AGE entry into cells by macropinocytosis may, in part,
be responsible for the downregulation of Na+K+ATPase by AGEs.
Furthermore, the downregulation of Na+K+ATPase was blocked by
a neutralising antibody to TGF-β, suggesting that preformed and/or
newly synthesised TGF-β is released by cells within 30 min of exposure
to AGE–BSA. This contrastswith theupregulation of TGF-β1 protein after
long-term (24 h) exposure to AGEs. Thus regulation of Na+K+ATPase
by AGE via TGF-β may be both short and long-term: by acute release
of preformed/newly synthesised TGF-β and by increased protein
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Fig. 8. Inhibitors of Arf6 and actin polymerisation prevent AGE-induced TGF-β1 protein
accumulation. HK2 cells were pretreated with 0.2% DMSO vehicle control, 2 μM cyto-
chalasin D or 2 μM Arf6(2–13) inhibitory peptide in SFM for 1 h before incubation
with 40 μM BSA (B) or AGE–BSA (A) for 24 h. CM was collected and assayed for active
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Fig. 6. AGE–BSA increases Tiam1 protein and activates PAK1. A LLC-PK1 cells were
incubated with 40 μM BSA or AGE–BSA for 24 h. Cell lysates were collected, separated
by SDS-10%-PAGE, and Tiam1 Western blotting performed. The blot shown is repre-
sentative of 3 independent experiments. B LLC-PK1 cells were incubated with 40 μM BSA
or AGE–BSA for 24 h. Cell lysateswere collected, immunoprecipitatedwith anti-PAK1 anti-
serum and a kinase reaction performed with MBP as the substrate. After SDS-14%-PAGE,
phosphorylated MBP was visualised by autoradiography. Experiments were performed 3
times. *p b 0.05 vs BSA.
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Fig. 7. Localisation of PIP2 and Arf6 to dorsal circular rufﬂes. LLC-PK1 cells were pre-treate
2 min. Cells were labeled for polymerised actin in dorsal circular rufﬂes using phalloidin-
and observed by ﬂuorescence microscopy. Bar 50 μm.
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AGE macropinocytosis on TGF-β and Na+K+ATPase may contribute to
EMT and ﬁbrosis. The mechanisms of TGF-β release and induction by
AGEs require further study.5. Conclusions
AGEs enter proximal tubule epithelial cells by macropinocytosis as
evidenced by: (i) amiloride-sensitive induction of uptake of high MW
dextran and AGE–BSA–FITC by AGE–BSA; (ii) AGE-induced circularARF6
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Fig. 9. PAK1 and PIP5Kγ siRNA inhibit AGE–BSA–FITC uptake and AGE-induced TGF-β1
protein accumulation. A HK2 cells were transfected without (−) or with control (CON)
or PAK1 siRNA for 48 h, lysates collected, and PAK1 Western blotting performed. The
blot shown is representative of 3 independent experiments. B Control, PAK1 or PIP5Kγ
siRNA-transfected cells were incubatedwith 100 μg/ml AGE–BSA–FITC for 45 min, lysates
collected and ﬂuorescence measured by spectroﬂuorometry. Experiments were
performed 3 times in triplicate and results normalised to protein content and expressed
as a percentage of control siRNA. *p b 0.05 vs control siRNA. C Control, PAK1 or PIP5Kγ
siRNA-transfected cells were incubated with 40 μM BSA (white) or AGE–BSA (black) for
24 h beforemeasurement of active TGF-β1 protein inCMbyELISA. Assayswere performed
3 times in triplicate and expressed as a percentage of BSA treated control siRNA-
transfected cells. *p b 0.05 vs BSA treated control siRNA, §p b 0.05, §§§p b 0.001 vs
AGE–BSA treated control siRNA, #p b 0.05 vs BSA treated PIP5Kγ siRNA.
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Fig. 10. Inhibitors of the Na+/H+ exchanger, actin polymerisation and Rac1 activation
reverse AGE-induced inhibition of surface expression of Na+K+ATPase. A LLC-PK1 cells
were pre-treated with 0.2% DMSO vehicle control, 0.16 mg/ml amiloride, 1 μM
cytochalasin D or 4.8 μM GGTI-287 for 30 min before incubation with 40 μM BSA or
AGE–BSA ± inhibitors for 30 min. B LLC-PK1 cells were pretreated with 30 μg/ml
anti-TGF-β or control antibody for 1 h before treatment with 40 μM BSA or AGE–
BSA ± antibodies for 30 min. Cells were ﬁxed and labeled with anti-Na+K+ATPase anti-
serum and a TRITC-labelled secondary antibody. Experiments were performed 3 times.
Nuclei were stained with DAPI. Bar 200 μm.
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PAK1. Macropinocytosis of AGE–BSA upregulates TGF-β1 levels and
contributes to AGE-induced downregulation of surface Na+K+ATPase,
suggesting that it may contribute to EMT of proximal tubule cells and
ﬁbrosis seen in diabetic kidney disease. Further studies are necessary
to elucidate the relationship between AGE entry by macropinocytosis,
the regulation of surface Na+K+ATPase, TGF-β1, ﬁbrosis, and EMT
in kidney epithelial cells. Linking cellular uptake of AGEs to
macropinocytosis, a speciﬁc endocytic process, also suggests a num-
ber of novel targets for diabetic nephropathy, namely Arf6, PIP5Kγ,
Tiam1, Rac1 and PAK1.
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